BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Naltrexone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Naltrexone\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05509257-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Naltrexone: Phase 1 readout est. (NCT05509257)
DESCRIPTION:Naltrexone\, phase 1.\nStudy: Naltrexone Neuroimaging in Teens 
 With Eating Disorders\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05509257
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04678895-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Naltrexone: Phase 2 readout est. (NCT04678895)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Low-Dose Naltrexone for the Treat
 ment of Painful Diabetic Neuropathy\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT046788
 95
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04649892-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Naltrexone: Phase 2 readout est. (NCT04649892)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Predicting Response to Naltrexone
  With Eye Tracking in Gaming Disorder\nEstimated primary completion: Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0464
 9892
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166071-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Naltrexone: Phase 1 readout est. (NCT04166071)
DESCRIPTION:Naltrexone\, phase 1.\nStudy: Opioids and Social Support Enhanc
 ed Extinction Effects\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04166071
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269873-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Naltrexone: Phase 1 readout est. (NCT07269873)
DESCRIPTION:Naltrexone\, phase 1.\nStudy: Safety and PK Study of BICX104 Wi
 th or Without Bupropion Compared to Vivitrol\nEstimated primary completion
 : 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/na
 ltrexone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07269873
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881485-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Naltrexone: Phase na readout est. (NCT06881485)
DESCRIPTION:Naltrexone\, phase na.\nStudy: Naltrexone/Bupropion With or Wit
 hout Very Low Calorie Ketogenic Diet for Weight Regain After Bariatric Sur
 gery\nEstimated primary completion: 1 January 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06881485
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622239-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Naltrexone: Phase 2 readout est. (NCT06622239)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Trial to Evaluate the Effects of 
 Naltrexone in Nonsuicidal Self-injury\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexo
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6622239
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07433413-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Naltrexone: Phase 3 readout est. (NCT07433413)
DESCRIPTION:Naltrexone\, phase 3.\nStudy: Evaluate the Efficacy and Safety 
 of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07433413
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06633900-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Naltrexone: Phase 2/3 readout est. (NCT06633900)
DESCRIPTION:Naltrexone\, phase 2/3.\nStudy: Naltrexone for Overdose Prevent
 ion\nEstimated primary completion: 15 April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06633900
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05537935-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Naltrexone: Phase 4 readout est. (NCT05537935)
DESCRIPTION:Naltrexone\, phase 4.\nStudy: Low Dose Naltrexone for Pain in P
 atients With HIV\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05537935
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05028062-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Naltrexone: Phase 4 readout est. (NCT05028062)
DESCRIPTION:Naltrexone\, phase 4.\nStudy: Naltrexone in AUD Reward Drinkers
 \nEstimated primary completion: July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05028062
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02502162-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Naltrexone: Phase na readout est. (NCT02502162)
DESCRIPTION:Naltrexone\, phase na.\nStudy: Low-Dose Naltrexone for the Trea
 tment of Complex Regional Pain Syndrome\nEstimated primary completion: Jul
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT025021
 62
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862400-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Naltrexone: Phase 2 readout est. (NCT07862400)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: A Pilot Study on the Efficacy of 
 Oral Low Dose Naltrexone for Vulvodynia\nEstimated primary completion: 1 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0786
 2400
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06306157-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Naltrexone: Phase 4 readout est. (NCT06306157)
DESCRIPTION:Naltrexone\, phase 4.\nStudy: Low Dose Naltrexone Therapy for C
 omplex Regional Pain Syndrome\nEstimated primary completion: August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06306157
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06366724-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Naltrexone: Phase 2 readout est. (NCT06366724)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: LIFT: Life Improvement Trial\nEst
 imated primary completion: September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06366724
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641283-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Naltrexone: Phase na readout est. (NCT07641283)
DESCRIPTION:Naltrexone\, phase na.\nStudy: Naltrexone for Nonsuicidal Self-
 Injury\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07641283
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224087-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Naltrexone: Phase 1 readout est. (NCT07224087)
DESCRIPTION:Naltrexone\, phase 1.\nStudy: Development of a MHBC Interventio
 n for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07224087
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06845124-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Naltrexone: Phase 2 readout est. (NCT06845124)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: A Trial to Investigate the Effect
 s of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcoh
 ol Dependence\nEstimated primary completion: 1 April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06845124
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285473-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Naltrexone: Phase 2 readout est. (NCT07285473)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Low-Dose Naltrexone For ME/CFS: D
 ose-Finding\nEstimated primary completion: 1 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07285473
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249554-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Naltrexone: Phase 2 readout est. (NCT07249554)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Combination Therapy for Alcohol U
 se Disorder\nEstimated primary completion: July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07249554
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05827159-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Naltrexone: Phase 3 readout est. (NCT05827159)
DESCRIPTION:Naltrexone\, phase 3.\nStudy: Emergency Department-Initiated Me
 dications for Alcohol Use Disorder\nEstimated primary completion: 1 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0582715
 9
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05940324-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Naltrexone: Phase 2 readout est. (NCT05940324)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Examining Mu Opioid Mechanisms of
  Ketamine's Rapid Effects in OCD (MKET2)\nEstimated primary completion: No
 vember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/naltrexo
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5940324
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06426303-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Naltrexone: Phase 4 readout est. (NCT06426303)
DESCRIPTION:Naltrexone\, phase 4.\nStudy: Sex Differences in Trauma\, Infla
 mmation and Brain Function and the Implications for Treatment Efficacy in 
 Alcohol Use Disorder\nEstimated primary completion: 31 December 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06426303
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224009-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Naltrexone: Phase 2 readout est. (NCT07224009)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Low Dose Naltrexone (LDN) for Man
 agement of Fatigue in Prostate Cancer Patients on Androgen Deprivation The
 rapy (ADT)\nEstimated primary completion: January 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07224009
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363514-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Naltrexone: Phase 4 readout est. (NCT05363514)
DESCRIPTION:Naltrexone\, phase 4.\nStudy: Low Dose Naltrexone Use in Patien
 ts With POTS\nEstimated primary completion: June 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05363514
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382091-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Naltrexone: Phase 2 readout est. (NCT05382091)
DESCRIPTION:Naltrexone\, phase 2.\nStudy: Evaluation of the O'Neil Long Act
 ing Naltrexone Implant in Opioid Dependent Persons\nEstimated primary comp
 letion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 naltrexone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05382091
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064564-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Naltrexone: Phase 1 readout est. (NCT07064564)
DESCRIPTION:Naltrexone\, phase 1.\nStudy: iSTEP-N 101b: Pharmacokinetics an
 d Safety Study of iSTEP-N Implant vs Monthly Vivitrol in Healthy Volunteer
 s\nEstimated primary completion: 1 October 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/naltrexone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07064564
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398404-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Naltrexone: Phase 1/2 readout est. (NCT07398404)
DESCRIPTION:Naltrexone\, phase 1/2.\nStudy: A Multiple Health Behavior Chan
 ge (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Baria
 tric Surgery Patients\nEstimated primary completion: 31 December 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/naltrexone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07398404
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221565-6547@assetmemo.bio
DTSTAMP:20261121T004034Z
DTSTART;VALUE=DATE:20341023
DTEND;VALUE=DATE:20341024
SUMMARY:Naltrexone: Phase 1/2 readout est. (NCT07221565)
DESCRIPTION:Naltrexone\, phase 1/2.\nStudy: Electromagnetic Immunotherapy M
 apping and Cytokine Forecasting Study (QSIT)\nEstimated primary completion
 : 23 October 2034. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/na
 ltrexone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07221565
URL:https://assetmemo.bio/drug/naltrexone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
